# A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416

> **NCT03283098** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 33 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Etelcalcetide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03283098
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2019-02-04
- **Final completion:** 2019-02-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283098, "A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03283098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*